New generation of chronic myeloid leukemia inhibitors

A new generation of BCR-ABL kinase inhibitor chmfl-abl-053 for chronic myeloid leukemia (CML) has been developed by experts from the strong magnetic field science center of Hefei Institute of material science, Chinese Academy of Sciences, which can effectively block the growth of tumor cells The research results were published online in the Journal of pharmaceutical chemistry, the core journal of pharmaceutical chemistry of the American Chemical Society Chronic myeloid leukemia (CML) is a kind of malignant tumor that affects the blood and bone marrow It is characterized by the production of a large number of immature white blood cells, which gather in the bone marrow and inhibit the normal hematopoiesis of the bone marrow Moreover, CML can spread through the blood in the whole body, resulting in anemia, bleeding and infection in patients At present, there are several targeted drugs for the treatment of chronic myeloid leukemia with ABL kinase as the target in clinic, but these drugs can not only inhibit ABL kinase, but also affect other kinases, which is easy to cause different side effects Based on the structure of kinase ABL, a new generation of BCR-ABL inhibitor chmfl-abl-053 was developed, which removed the influence on other kinases, and improved the selectivity and activity of drugs to ABL kinases Chmfl-abl-053 can effectively inhibit the proliferation of chronic myeloid leukemia cancer cells, and effectively block the growth of tumor in mouse tumor experiments It is understood that the research results have applied for Chinese invention patents and PCT (patent cooperation agreement) international applications, and are jointly developing national first-class innovative drugs with relevant pharmaceutical industries The research was supported by the youth thousand talents program of the Central Organization Department, the Hundred Talents Program of the Chinese Academy of Sciences, and the Natural Science Youth Fund.